Difference	B:C1710191
-	I:C1710191
in-	I:C1710191
Differences	I:C1710191
Method	I:C1710191
in	O
Comparative	O
Effectiveness	I:C2718022
Research	I:C2718022
:	O
Utility	O
with	O
Unbalanced	O
Groups	O
.	O

Difference	O
-	I:C1710191
in-	I:C1710191
Differences	I:C1710191
Method	I:C1710191
in	O
Comparative	B:C2718022
Effectiveness	I:C2718022
Research	I:C2718022
:	O
Utility	O
with	O
Unbalanced	O
Groups	O
.	O

Comparative	B:C2718022
effectiveness	I:C2718022
research	I:C2718022
(	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
)	O
often	O
includes	O
observational	O
studies	I:C3658316
utilizing	O
administrative	O
data	I:C1320722
.	O

Comparative	O
effectiveness	I:C2718022
research	I:C2718022
(	O
Comparative	B:C2718022
effectiveness	I:C2718022
research	I:C2718022
)	O
often	O
includes	O
observational	O
studies	I:C3658316
utilizing	O
administrative	O
data	I:C1320722
.	O

Comparative	O
effectiveness	I:C2718022
research	I:C2718022
(	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
)	O
often	O
includes	O
observational	B:C3658316
studies	I:C3658316
utilizing	O
administrative	O
data	I:C1320722
.	O

Comparative	O
effectiveness	I:C2718022
research	I:C2718022
(	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
)	O
often	O
includes	O
observational	O
studies	I:C3658316
utilizing	O
administrative	B:C1320722
data	I:C1320722
.	O

Multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
Comparative	B:C2718022
effectiveness	I:C2718022
research	I:C2718022
to	O
adjust	O
for	O
group	O
differences	O
,	O
including	O
difference	O
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
(	I:C1710191
DiD	I:C1710191
)	I:C1710191
estimation	I:C1710191
.	O

Multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
to	O
adjust	O
for	O
group	O
differences	O
,	O
including	O
difference	B:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
(	I:C1710191
DiD	I:C1710191
)	I:C1710191
estimation	I:C1710191
.	O

This	O
study	O
presents	O
differences	B:C1710191
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
setting	O
by	O
utilizing	O
the	O
MarketScan®	O
Databases	I:C0242356
for	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
patients	O
receiving	O
different	O
therapies	O
.	O

This	O
study	O
presents	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	B:C0025663
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
setting	O
by	O
utilizing	O
the	O
MarketScan®	O
Databases	I:C0242356
for	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
patients	O
receiving	O
different	O
therapies	O
.	O

This	O
study	O
presents	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
Comparative	B:C2718022
effectiveness	I:C2718022
research	I:C2718022
setting	O
by	O
utilizing	O
the	O
MarketScan®	O
Databases	I:C0242356
for	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
patients	O
receiving	O
different	O
therapies	O
.	O

This	O
study	O
presents	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
setting	O
by	O
utilizing	O
the	O
MarketScan®	B:C0242356
Databases	I:C0242356
for	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
patients	O
receiving	O
different	O
therapies	O
.	O

This	O
study	O
presents	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
setting	O
by	O
utilizing	O
the	O
MarketScan®	O
Databases	I:C0242356
for	O
multiple	B:C0026769
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
patients	O
receiving	O
different	O
therapies	O
.	O

This	O
study	O
presents	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
setting	O
by	O
utilizing	O
the	O
MarketScan®	O
Databases	I:C0242356
for	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	B:C0026769
sclerosis	I:C0026769
)	O
patients	O
receiving	O
different	O
therapies	O
.	O

This	O
study	O
presents	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
Comparative	O
effectiveness	I:C2718022
research	I:C2718022
setting	O
by	O
utilizing	O
the	O
MarketScan®	O
Databases	I:C0242356
for	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
patients	O
receiving	O
different	O
therapies	B:C0087111
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	B:C2348484
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	O
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	B:C0289884
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	O
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	B:C0289884
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	O
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	B:C2936279
to	O
fingolimod	O
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	B:C1699926
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	O
(	O
FTY	B:C1699926
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	O
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	B:C0289884
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	O
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	B:C0243095
switch	I:C0243095
)	O
from	O
a	O
US	O
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	I:C2348484
[	O
glatiramer	O
acetate	I:C0289884
(	O
glatiramer	O
acetate	I:C0289884
)	O
switched	O
to	O
fingolimod	O
(	O
FTY	O
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
glatiramer	O
acetate	I:C0289884
only	O
,	O
no	O
switch	I:C0243095
)	O
from	O
a	O
US	B:C0242356
administrative	I:C0242356
claims	I:C0242356
database	I:C0242356
.	O

A	O
trend	O
analysis	O
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	B:C0034980
to	O
the	O
mean	O
and	O
to	O
compare	O
relapse	O
rates	O
among	O
treatment	O
cohorts	I:C2348484
.	O

A	O
trend	O
analysis	O
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	O
to	O
the	O
mean	O
and	O
to	O
compare	O
relapse	O
rates	O
among	O
treatment	B:C2348484
cohorts	I:C2348484
.	O

DiD	B:C1710191
analysis	I:C1710191
was	O
used	O
to	O
enable	O
comparisons	O
among	O
the	O
Test	O
and	O
Control	O
Cohorts	O
.	O

DiD	O
analysis	I:C1710191
was	O
used	O
to	O
enable	O
comparisons	O
among	O
the	O
Test	B:C2348484
and	O
Control	O
Cohorts	O
.	O

Logistic	B:C0206031
regression	I:C0206031
was	O
used	O
to	O
estimate	O
the	O
probability	O
of	O
relapse	O
after	O
switching	O
from	O
glatiramer	O
acetate	I:C0289884
to	O
FTY	O
,	O
and	O
to	O
compare	O
group	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
index	O
periods	O
.	O

Logistic	O
regression	I:C0206031
was	O
used	O
to	O
estimate	O
the	O
probability	O
of	O
relapse	O
after	O
switching	B:C2936279
from	O
glatiramer	O
acetate	I:C0289884
to	O
FTY	O
,	O
and	O
to	O
compare	O
group	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
index	O
periods	O
.	O

Logistic	O
regression	I:C0206031
was	O
used	O
to	O
estimate	O
the	O
probability	O
of	O
relapse	O
after	O
switching	O
from	O
glatiramer	B:C0289884
acetate	I:C0289884
to	O
FTY	O
,	O
and	O
to	O
compare	O
group	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
index	O
periods	O
.	O

Logistic	O
regression	I:C0206031
was	O
used	O
to	O
estimate	O
the	O
probability	O
of	O
relapse	O
after	O
switching	O
from	O
glatiramer	O
acetate	I:C0289884
to	O
FTY	B:C1699926
,	O
and	O
to	O
compare	O
group	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
index	O
periods	O
.	O

Crude	O
DiD	B:C1710191
analysis	I:C1710191
showed	O
that	O
in	O
the	O
pre	O
-	O
index	O
period	O
more	O
patients	O
in	O
the	O
Test	O
Cohort	I:C2348484
experienced	O
an	O
multiple	O
sclerosis	I:C0026769
relapse	O
and	O
had	O
a	O
higher	O
mean	O
number	O
of	O
relapses	O
than	O
in	O
the	O
Control	O
Cohort	O
.	O

Crude	O
DiD	O
analysis	I:C1710191
showed	O
that	O
in	O
the	O
pre	O
-	O
index	O
period	O
more	O
patients	O
in	O
the	O
Test	B:C2348484
Cohort	I:C2348484
experienced	O
an	O
multiple	O
sclerosis	I:C0026769
relapse	O
and	O
had	O
a	O
higher	O
mean	O
number	O
of	O
relapses	O
than	O
in	O
the	O
Control	O
Cohort	O
.	O

Crude	O
DiD	O
analysis	I:C1710191
showed	O
that	O
in	O
the	O
pre	O
-	O
index	O
period	O
more	O
patients	O
in	O
the	O
Test	O
Cohort	I:C2348484
experienced	O
an	O
multiple	B:C0026769
sclerosis	I:C0026769
relapse	O
and	O
had	O
a	O
higher	O
mean	O
number	O
of	O
relapses	O
than	O
in	O
the	O
Control	O
Cohort	O
.	O

During	O
the	O
pre	O
-	O
index	O
period	O
,	O
numeric	O
and	O
relative	O
data	O
for	O
multiple	B:C0026769
sclerosis	I:C0026769
relapses	O
in	O
patients	O
in	O
the	O
Test	O
Cohort	I:C2348484
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control	O
Cohort	O
,	O
while	O
no	O
significant	I:C1273937
between	O
-	O
group	O
differences	O
emerged	O
during	O
the	O
post	O
-	O
index	O
period	O
.	O

During	O
the	O
pre	O
-	O
index	O
period	O
,	O
numeric	O
and	O
relative	O
data	O
for	O
multiple	O
sclerosis	I:C0026769
relapses	O
in	O
patients	O
in	O
the	O
Test	B:C2348484
Cohort	I:C2348484
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control	O
Cohort	O
,	O
while	O
no	O
significant	I:C1273937
between	O
-	O
group	O
differences	O
emerged	O
during	O
the	O
post	O
-	O
index	O
period	O
.	O

During	O
the	O
pre	O
-	O
index	O
period	O
,	O
numeric	O
and	O
relative	O
data	O
for	O
multiple	O
sclerosis	I:C0026769
relapses	O
in	O
patients	O
in	O
the	O
Test	O
Cohort	I:C2348484
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control	O
Cohort	O
,	O
while	O
no	B:C1273937
significant	I:C1273937
between	O
-	O
group	O
differences	O
emerged	O
during	O
the	O
post	O
-	O
index	O
period	O
.	O

Generalized	O
linear	O
modeling	O
with	O
differences	B:C1710191
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
regression	O
estimation	O
showed	O
that	O
the	O
mean	O
number	O
of	O
multiple	O
sclerosis	I:C0026769
relapses	O
decreased	O
significantly	O
in	O
the	O
post	O
-	O
index	O
period	O
among	O
patients	O
in	O
the	O
Test	O
Cohort	I:C2348484
compared	O
with	O
patients	O
in	O
the	O
Control	O
Cohort	O
.	O

Generalized	O
linear	O
modeling	O
with	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
regression	O
estimation	O
showed	O
that	O
the	O
mean	O
number	O
of	O
multiple	B:C0026769
sclerosis	I:C0026769
relapses	O
decreased	O
significantly	O
in	O
the	O
post	O
-	O
index	O
period	O
among	O
patients	O
in	O
the	O
Test	O
Cohort	I:C2348484
compared	O
with	O
patients	O
in	O
the	O
Control	O
Cohort	O
.	O

Generalized	O
linear	O
modeling	O
with	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
regression	O
estimation	O
showed	O
that	O
the	O
mean	O
number	O
of	O
multiple	O
sclerosis	I:C0026769
relapses	O
decreased	O
significantly	O
in	O
the	O
post	O
-	O
index	O
period	O
among	O
patients	O
in	O
the	O
Test	B:C2348484
Cohort	I:C2348484
compared	O
with	O
patients	O
in	O
the	O
Control	O
Cohort	O
.	O

In	O
this	O
study	O
,	O
an	O
multiple	B:C0026769
sclerosis	I:C0026769
population	O
was	O
utilized	O
to	O
demonstrate	O
how	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
can	O
be	O
applied	O
to	O
estimate	O
treatment	O
effects	I:C1518681
in	O
a	O
heterogeneous	O
population	O
,	O
where	O
the	O
Test	O
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O

In	O
this	O
study	O
,	O
an	O
multiple	O
sclerosis	I:C0026769
population	B:C1257890
was	O
utilized	O
to	O
demonstrate	O
how	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
can	O
be	O
applied	O
to	O
estimate	O
treatment	O
effects	I:C1518681
in	O
a	O
heterogeneous	O
population	O
,	O
where	O
the	O
Test	O
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O

In	O
this	O
study	O
,	O
an	O
multiple	O
sclerosis	I:C0026769
population	O
was	O
utilized	O
to	O
demonstrate	O
how	O
differences	B:C1710191
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
can	O
be	O
applied	O
to	O
estimate	O
treatment	O
effects	I:C1518681
in	O
a	O
heterogeneous	O
population	O
,	O
where	O
the	O
Test	O
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O

In	O
this	O
study	O
,	O
an	O
multiple	O
sclerosis	I:C0026769
population	O
was	O
utilized	O
to	O
demonstrate	O
how	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
can	O
be	O
applied	O
to	O
estimate	O
treatment	B:C1518681
effects	I:C1518681
in	O
a	O
heterogeneous	O
population	O
,	O
where	O
the	O
Test	O
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O

In	O
this	O
study	O
,	O
an	O
multiple	O
sclerosis	I:C0026769
population	O
was	O
utilized	O
to	O
demonstrate	O
how	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
can	O
be	O
applied	O
to	O
estimate	O
treatment	O
effects	I:C1518681
in	O
a	O
heterogeneous	O
population	B:C1257890
,	O
where	O
the	O
Test	O
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O

In	O
this	O
study	O
,	O
an	O
multiple	O
sclerosis	I:C0026769
population	O
was	O
utilized	O
to	O
demonstrate	O
how	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
can	O
be	O
applied	O
to	O
estimate	O
treatment	O
effects	I:C1518681
in	O
a	O
heterogeneous	O
population	O
,	O
where	O
the	O
Test	B:C2348484
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O

The	O
results	O
show	O
that	O
differences	B:C1710191
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
offers	O
a	O
robust	O
method	O
for	O
comparing	O
diverse	O
cohorts	O
when	O
other	O
risk	O
-	O
adjustment	O
methods	O
may	O
not	O
be	O
adequate	O
.	O

The	O
results	O
show	O
that	O
differences	O
,	I:C1710191
including	I:C1710191
difference	I:C1710191
-	I:C1710191
in	I:C1710191
-	I:C1710191
differences	I:C1710191
offers	O
a	O
robust	O
method	O
for	O
comparing	O
diverse	O
cohorts	B:C0599755
when	O
other	O
risk	O
-	O
adjustment	O
methods	O
may	O
not	O
be	O
adequate	O
.	O

